These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25998051)

  • 1. Selective delivery of therapeutic single strand antimiRs by aptamer-based conjugates.
    Catuogno S; Rienzo A; Di Vito A; Esposito CL; de Franciscis V
    J Control Release; 2015 Jul; 210():147-59. PubMed ID: 25998051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells.
    Esposito CL; Nuzzo S; Kumar SA; Rienzo A; Lawrence CL; Pallini R; Shaw L; Alder JE; Ricci-Vitiani L; Catuogno S; de Franciscis V
    J Control Release; 2016 Sep; 238():43-57. PubMed ID: 27448441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.
    Esposito CL; Cerchia L; Catuogno S; De Vita G; Dassie JP; Santamaria G; Swiderski P; Condorelli G; Giangrande PH; de Franciscis V
    Mol Ther; 2014 Jun; 22(6):1151-1163. PubMed ID: 24441398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo.
    Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM
    Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle-complexed antimiRs for inhibiting tumor growth and metastasis in prostate carcinoma and melanoma.
    Kunz M; Brandl M; Bhattacharya A; Nobereit-Siegel L; Ewe A; Weirauch U; Hering D; Reinert A; Kalwa H; Guzman J; Weigelt K; Wach S; Taubert H; Aigner A
    J Nanobiotechnology; 2020 Nov; 18(1):173. PubMed ID: 33228711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to train your dragon: targeted delivery of microRNA to cancer cells in vivo.
    Kortylewski M; Nechaev S
    Mol Ther; 2014 Jun; 22(6):1070-1071. PubMed ID: 24881764
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting Axl with an high-affinity inhibitory aptamer.
    Cerchia L; Esposito CL; Camorani S; Rienzo A; Stasio L; Insabato L; Affuso A; de Franciscis V
    Mol Ther; 2012 Dec; 20(12):2291-303. PubMed ID: 22910292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer.
    Camorani S; Esposito CL; Rienzo A; Catuogno S; Iaboni M; Condorelli G; de Franciscis V; Cerchia L
    Mol Ther; 2014 Apr; 22(4):828-41. PubMed ID: 24566984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer.
    Camorani S; Hill BS; Collina F; Gargiulo S; Napolitano M; Cantile M; Di Bonito M; Botti G; Fedele M; Zannetti A; Cerchia L
    Theranostics; 2018; 8(18):5178-5199. PubMed ID: 30429893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
    Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
    Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective.
    Vandghanooni S; Eskandani M; Barar J; Omidi Y
    J Mol Med (Berl); 2018 Sep; 96(9):885-902. PubMed ID: 30056527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.
    Wang Y; Xia H; Zhuang Z; Miao L; Chen X; Cai H
    Cell Death Dis; 2014 May; 5(5):e1227. PubMed ID: 24832599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
    Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
    Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
    Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
    Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA H19 regulates HIF-1α/AXL signaling through inhibiting miR-20b-5p in endometrial cancer.
    Zhu H; Jin YM; Lyu XM; Fan LM; Wu F
    Cell Cycle; 2019 Oct; 18(19):2454-2464. PubMed ID: 31411527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer?
    Dransfield I; Farnworth S
    Adv Exp Med Biol; 2016; 930():113-32. PubMed ID: 27558819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.
    Camorani S; Crescenzi E; Fedele M; Cerchia L
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):263-277. PubMed ID: 29574128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.
    El Bezawy R; De Cesare M; Pennati M; Deraco M; Gandellini P; Zuco V; Zaffaroni N
    J Hematol Oncol; 2017 Jan; 10(1):19. PubMed ID: 28100259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL.
    Li R; Shi X; Ling F; Wang C; Liu J; Wang W; Li M
    Tumour Biol; 2015 Sep; 36(9):7277-83. PubMed ID: 25895459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyfluoroalkyl Tag Decoration Enables Significantly Enhanced Tumor Penetration Ability of a PTK7 Targeting Aptamer.
    Li Y; Zhang C; Fu T; Wang XQ; Tan W
    Bioconjug Chem; 2024 May; 35(5):674-681. PubMed ID: 38695582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.